Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ] - Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012
Fri, July 6, 2012
Thu, July 5, 2012
Wed, July 4, 2012
[ Wed, Jul 04th 2012 ] - Market Wire
Warnex Announces Refinancing
Tue, July 3, 2012
Mon, July 2, 2012
Sun, July 1, 2012
Fri, June 29, 2012
Thu, June 28, 2012
Wed, June 27, 2012

Questcor to Report Second Quarter Results on July 24, 2012


//health-fitness.news-articles.net/content/2012/ .. port-second-quarter-results-on-july-24-2012.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Questcor to Report Second Quarter Results on July 24, 2012 -- ANAHEIM, Calif., July 10, 2012 /PRNewswire/ --

Questcor to Report Second Quarter Results on July 24, 2012

[ ]

ANAHEIM, Calif., July 10, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: [ QCOR ]) today announced that it will release second quarter 2012 financial results on Tuesday, July 24, 2012 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, July 24, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments. The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website: [ http://ir.questcor.com/ ].
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-941-9205. For participants outside the U.S., the dial-in number is 480-629-9819.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The dial-in number for U.S. participants is 800-406-7325. For participants outside the U.S., the replay dial-in number is 303-590-3030. The replay access code for all callers is 4550797#.

About Questcor                                                                                    

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently preparing to launch a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit [ www.questcor.com ].

SOURCE Questcor Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.questcor.com ]


Publication Contributing Sources